| Host |
Rat |
| Klon |
MAC353 |
| Format |
TCS |
| Methode |
F, EL, IP |
| Isotyp |
Rat IgG2b |
| Verdünnung |
71 amino acid fusion protein corresponding to the C-terminal region of M31 |
M31 (Mouse)/ HP1 (Human)
|
Zytomed Systems GmbH |
MAC353 |
2 ml |
TCS |
RUO |
613-0003 |
-
|
| Host |
Mouse |
| Klon |
MAC387 |
| Format |
Purified |
| Methode |
F, P, FL |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Human Spleen |
| Verdünnung |
1:100 - 1:200 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human monocytes |
Macrophage
|
Zytomed Systems GmbH |
MAC387 |
200 µg |
Purified |
RUO |
613-0005 |
-
|
| Host |
Mouse |
| Klon |
MAC387 |
| Format |
Purified |
| Methode |
F, P, FL |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Human Spleen |
| Verdünnung |
1:100 - 1:200 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human monocytes |
Macrophage
|
Zytomed Systems GmbH |
MAC387 |
100 µg |
Purified |
RUO |
613-0006 |
-
|
| Host |
Mouse |
| Klon |
314G8 |
| Format |
Purified |
| Methode |
F, EL |
| Verdünnung |
1:25 : 1:200 (F) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Recombinant soluble MadCAM-1-fc fusion protein |
MAdCAM-1 (Mucosal Addressin Cell Adhesion Molecule 1)
|
Zytomed Systems GmbH |
314G8 |
200 µg |
Purified |
RUO |
613-0019 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:200 |
| Isotyp |
Mouse IgG |
| Verdünnung |
Full length recombinant human MAGE-1 protein. |
| Lokalisation |
Cytoplasm |
MAGE-1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
513-4504 |
-
|
| Host |
Mouse |
| Klon |
304-1A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
304-1A5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2007ML |
-
|
| Host |
Mouse |
| Klon |
304-1A5 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
304-1A5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2007MP |
-
|
| Host |
Mouse |
| Klon |
304-1A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
304-1A5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2007MS |
-
|
| Host |
Mouse |
| Klon |
304-1A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
304-1A5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2007MT |
-
|
| Host |
Rabbit |
| Klon |
31A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
31A5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2009RL |
-
|
| Host |
Rabbit |
| Klon |
31A5 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
31A5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2009RP |
-
|
| Host |
Rabbit |
| Klon |
31A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
31A5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2009RS |
-
|
| Host |
Rabbit |
| Klon |
31A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
31A5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2009RT |
-
|
| Host |
Rabbit |
| Klon |
ZR363 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human Mammaglobin (SCGB2A2) protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
ZR363 |
1 ml |
Concentrate |
CE/IVD |
Z2739RL |
-
|
| Host |
Rabbit |
| Klon |
ZR363 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human Mammaglobin (SCGB2A2) protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
ZR363 |
7 ml |
Concentrate |
CE/IVD |
Z2739RP |
-
|
| Host |
Rabbit |
| Klon |
ZR363 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human Mammaglobin (SCGB2A2) protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
ZR363 |
0.5 ml |
Concentrate |
CE/IVD |
Z2739RS |
-
|
| Host |
Rabbit |
| Klon |
ZR363 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human Mammaglobin (SCGB2A2) protein |
| Lokalisation |
Cytoplasm |
Mammaglobin
|
Zeta Corporation |
ZR363 |
0.1 ml |
Concentrate |
CE/IVD |
Z2739RT |
-
|
| Host |
Mouse and Rabbit |
| Klon |
304-1A5 & 31-A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1/κ /Rabbit IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin Cocktail
|
Zeta Corporation |
304-1A5 & 31-A5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2011MRL |
-
|
| Host |
Mouse and Rabbit |
| Klon |
304-1A5 & 31-A5 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1/κ /Rabbit IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin Cocktail
|
Zeta Corporation |
304-1A5 & 31-A5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2011MRP |
-
|
| Host |
Mouse and Rabbit |
| Klon |
304-1A5 & 31-A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1/κ /Rabbit IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin Cocktail
|
Zeta Corporation |
304-1A5 & 31-A5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2011MRS |
-
|
| Host |
Mouse and Rabbit |
| Klon |
304-1A5 & 31-A5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal or neoplastic breast tissue. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1/κ /Rabbit IgG |
| Verdünnung |
Recombinant full-length protein |
| Lokalisation |
Cytoplasm |
Mammaglobin Cocktail
|
Zeta Corporation |
304-1A5 & 31-A5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2011MRT |
-
|
| Host |
Rabbit |
| Klon |
SP177 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate adenocarcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human MAP4K4 protein |
| Lokalisation |
Cytoplasm |
MAP4K4
|
Zytomed Systems GmbH |
SP177 |
0.5 ml |
Concentrate |
RUO |
514-4772 |
-
|
| Host |
Rabbit |
| Klon |
SP177 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate adenocarcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human MAP4K4 protein |
| Lokalisation |
Cytoplasm |
MAP4K4
|
Zytomed Systems GmbH |
SP177 |
1 ml |
Concentrate |
RUO |
514-4774 |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:20 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
MART-1 (Melan-A)
|
Diagnostic Biosystems |
A103 |
1 ml |
Concentrate |
CE/IVD |
MOB277 |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:20 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
MART-1 (Melan-A)
|
Diagnostic Biosystems |
A103 |
0.1 ml |
Concentrate |
CE/IVD |
MOB277-01 |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:20 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
MART-1 (Melan-A)
|
Diagnostic Biosystems |
A103 |
0.5 ml |
Concentrate |
CE/IVD |
MOB277-05 |
-
|
| Host |
Mouse |
| Klon |
A103 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
MART-1 (Melan-A)
|
Diagnostic Biosystems |
A103 |
6 ml |
Ready-to-use |
CE/IVD |
PDM153 |
-
|
| Host |
Mouse + Rabbit |
| Klon |
M2-7C10 + M2-9E3 + T311 + BC37 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
IgG2b + IgG2a + IgG |
| Lokalisation |
Cytoplasm, nucleus (pHH3) |
MART-1 + Tyrosinase + pHH3
|
Biocare Medical |
M2-7C10 + M2-9E3 + T311 + BC37 |
6 ml |
Ready-to-use |
CE/IVD |
API3186DSAA |
-
|
| Host |
Mouse |
| Klon |
M2-7C10 + M2-9E3 + T311 + BC34 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
IgG2b + IgG2a + IgG1 |
| Lokalisation |
Cytoplasm + nucleus |
MART-1 + Tyrosinase + SOX10
|
Biocare Medical |
M2-7C10 + M2-9E3 + T311 + BC34 |
6 ml |
Ready-to-use |
CE/IVD |
API3165AA |
-
|
| Host |
Mouse |
| Klon |
M2-9E3 + T311 + BC34 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
IgG2b + IgG2a + IgG1 |
| Lokalisation |
Cytoplasm, cytoplasm, nucleus |
MART-1 + Tyrosinase + SOX10
|
Biocare Medical |
M2-9E3 + T311 + BC34 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3216G |
-
|
| Host |
Mouse |
| Klon |
24B72D11.1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Small cell lung cancer |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
MASH1
|
Biocare Medical |
24B72D11.1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3131A |
-
|
| Host |
Mouse |
| Klon |
24B72D11.1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Small cell lung cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
MASH1
|
Biocare Medical |
24B72D11.1 |
6 ml |
Ready-to-use |
CE/IVD |
API3131AA |
-
|
| Host |
Mouse |
| Klon |
CC1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Chymase
|
Diagnostic Biosystems |
CC1 |
1 ml |
Concentrate |
CE/IVD |
MOB346 |
-
|
| Host |
Mouse |
| Klon |
CC1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Chymase
|
Diagnostic Biosystems |
CC1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB346-01 |
-
|
| Host |
Mouse |
| Klon |
CC1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Chymase
|
Diagnostic Biosystems |
CC1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB346-05 |
-
|
| Host |
Mouse |
| Klon |
CC1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Chymase
|
Diagnostic Biosystems |
CC1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM159 |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
concentrate |
| Methode |
P |
| Positivkontrolle |
Endometrial Cancer |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic |
Mast Cell Tryptase
|
Biocare Medical |
AA1 |
0.1 ml |
concentrate |
RUO |
ACI3277A |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Tryptase
|
Diagnostic Biosystems |
AA1 |
1 ml |
Concentrate |
CE/IVD |
MOB347 |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Tryptase
|
Diagnostic Biosystems |
AA1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB347-01 |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Tryptase
|
Diagnostic Biosystems |
AA1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB347-05 |
-
|
| Host |
Mouse |
| Klon |
AA1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Mast Cell Tryptase
|
Diagnostic Biosystems |
AA1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM160 |
-
|
| Host |
Mouse |
| Klon |
OTI8A11+UMAB146 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil or normal cervix |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b+ Mouse IgG1 |
| Lokalisation |
Nuclear |
MCM2 + TOP2A
|
Biocare Medical |
OTI8A11+UMAB146 |
7 ml |
Ready-to-use |
RUO |
ALR3181G7 |
-
|
| Host |
Mouse |
| Klon |
OTI8A11+UMAB146 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil or normal cervix |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b+ Mouse IgG1 |
| Lokalisation |
Cytoplasm and cell membrane |
MCM2 + TOP2A
|
Biocare Medical |
OTI8A11+UMAB146 |
6 ml |
Ready-to-use |
CE/IVD |
API3181AA |
-
|
| Host |
Mouse |
| Klon |
OTI8A11+UMAB146 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil or normal cervix |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b+ Mouse IgG1 |
| Lokalisation |
Cytoplasm and cell membrane |
MCM2 + TOP2A
|
Biocare Medical |
OTI8A11+UMAB146 |
25 ml |
Ready-to-use |
CE/IVD |
API3181H |
-
|
| Host |
Mouse |
| Klon |
OTI8A11+UMAB146 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil or normal cervix |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b+ Mouse IgG1 |
| Lokalisation |
Nuclear |
MCM2 + TOP2A
|
Biocare Medical |
OTI8A11+UMAB146 |
6 ml |
Ready-to-use |
RUO |
AVR3181G |
-
|
| Host |
Rabbit |
| Klon |
ZR258 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
sample known to contain MDM2 protein |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human MDM2 protein fragment |
| Lokalisation |
Nucleus |
MDM2
|
Zeta Corporation |
ZR258 |
1 ml |
Concentrate |
RUO |
Z2572RL-R |
-
|
| Host |
Rabbit |
| Klon |
ZR258 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
sample known to contain MDM2 protein |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human MDM2 protein fragment |
| Lokalisation |
Nucleus |
MDM2
|
Zeta Corporation |
ZR258 |
7 ml |
ready-to-use |
RUO |
Z2572RP-R |
-
|
| Host |
Rabbit |
| Klon |
ZR258 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
sample known to contain MDM2 protein |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human MDM2 protein fragment |
| Lokalisation |
Nucleus |
MDM2
|
Zeta Corporation |
ZR258 |
0.5 ml |
Concentrate |
RUO |
Z2572RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR258 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
sample known to contain MDM2 protein |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human MDM2 protein fragment |
| Lokalisation |
Nucleus |
MDM2
|
Zeta Corporation |
ZR258 |
0.1 ml |
Concentrate |
RUO |
Z2572RT-R |
-
|
| Host |
Mouse |
| Klon |
3G187 |
| Format |
Concentrate |
| Methode |
P, WB, IF |
| Vorbehandlung |
Citrate |
| Verdünnung |
1:100 - 1:500 |
| Isotyp |
Mouse IgG2b kappa |
| Verdünnung |
A synthetic peptide corresponding to the N-terminus of human MDM2rom human MDM2 protein |
| Lokalisation |
nuclear |
MDM2 (Murine Double Minute 2)
|
Zytomed Systems GmbH |
3G187 |
50 µg (0.1 ml) |
Concentrate |
RUO |
113-0230 |
-
|